Medinet (2370) · InitiativeSetup progresses while service launch is delayedLatest Revision of earnings forecasts (2026-10-16): "Worsened"
Commercialization of a Cryopreserved Product Using Adipose-Derived Mesenchymal Stem Cells
First written in FY2025-H1. 2 of 5 entries say "Advanced", first in 2026-05-27. Latest entry: 2026-10-16.
5entries
2years
3from disclosures
How it moved
Same theme, other companies
Commercialization of an adipose-derived mesenchymal stem cell cryopreserved productA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025Setup progresses while service launch is delayedAnnual report
「The start of provision of a new cell-processing service using adipose-derived mesenchymal stromal cells (ASC) was delayed.」
The company carried out setup work toward starting contract manufacturing for ASC, but the start of provision was delayed. - FY2025-H1First statedAnnual report
「During the interim accounting period, we conducted preclinical studies, obtained data on cell quality and advanced manufacturing setup work with the aim of commercializing a frozen product using adipose-derived mesenchymal stem cells.」
The Company is conducting preclinical studies, obtaining quality data and preparing manufacturing setup for a frozen product using adipose-derived mesenchymal stem cells.